Categories
Change Password!
Reset Password!
Semaglutide is formally recognized by AASLD as a clinically meaningful therapy for moderate-to-advanced MASH, bridging metabolic control with fibrosis improvement through evidence-based guidance.
Metabolic dysfunction associated steatohepatitis (MASH) continues to accelerate fibrosis progression within metabolic dysfunction associated steatotic liver disease (MASLD), emerging as a major contributor to advanced liver disease and transplant risk. Despite rising prevalence, therapeutic options capable of reversing histologic injury while avoiding routine liver biopsy remain limited in real-world practice.
To address this unmet need, the updated American Association for the Study of Liver Diseases (AASLD) practice guidance was developed to incorporate evolving phase 3 evidence and recent regulatory decisions, with the aim of defining the clinical role of semaglutide, optimizing patient selection, and standardizing safety and response monitoring in moderate-to-advanced MASH. The recommendations were informed by interim outcomes from a randomized trial and supported by contemporary clinical data. To enhance real-world applicability, the guidance emphasized noninvasive tests (NITs), including:
For patients with borderline values (VCTE 15–20 kPa, MRE 4.4–5.0 kPa, ELF 10.5–11.3), treatment decisions were individualized based on confirmatory NITs, cross-sectional imaging excluding portal hypertension, or platelet counts above 150,000/mm³. Cirrhotic patients were excluded from semaglutide initiation for MASH, although those receiving it for other approved indications were closely monitored.
In ESSENCE, semaglutide administered as a 2.4 mg once-weekly subcutaneous injection for 72 weeks demonstrated statistically and clinically significant histologic benefits compared with placebo:
The therapy showed a favorable hepatic safety profile, with no treatment discontinuations related to liver enzyme elevations. The most commonly noted adverse events were vomiting, gastrointestinal nausea, diarrhea, and constipation, which were generally mild, transient, and improved with dose titration. Longitudinal improvements in NITs supported treatment response, including:
(a) VCTE least squares mean ≥30%
(b) MRE least squares mean ≥20%
(c) ELF score ≥0.5
The updated AASLD guidance translated the data into a practical, biopsy-sparing framework for MASH management, reinforcing semaglutide as a clinically meaningful option for patients with F2–F3 fibrosis. By combining quantified histologic benefit, NITs, and structured safety oversight, the recommendations advanced a more precise and scalable approach to treating metabolic liver disease, while acknowledging the need for continued long-term outcome data.
Hepatology
Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance
Meena B Bansal et al.
Comments (0)